NoGeneST™ Anti-PDGFRβ Aptamer, aPDGFRβ aptamer-1 sodium

Name: NoGeneST™ Anti-PDGFRβ Aptamer, aPDGFRβ aptamer-1 sodium
SKU: NRYF-0625-HZ49
Rating: 5 (1 reviews)

[CAT#: NRYF-0625-HZ49]

A nuclease-resistant DNA aptamer that acts as an antagonist of Platelet-Derived Growth Factor Receptor β (PDGFRβ).

Target:: PDGFRβ

Type:: DNA

Datasheet MSDS Request COA

Certificate of Analysis Lookup
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number

Inquiry

Product Overview

Description

This is a synthetic, nuclease-resistant DNA aptamer engineered to specifically bind to Platelet-Derived Growth Factor Receptor β (PDGFRβ). By acting as an antagonist, it blocks the receptor's downstream signaling pathways, which are involved in cell growth, proliferation, and migration. Its ability to target PDGFRβ makes it a valuable tool for research in oncology, particularly for tumors where this receptor is overexpressed, such as glioblastoma.

Type

DNA

Properties

Size

1 mg; 5 mg; 10 mg

Appearance

Supplied as a lyophilized white to off-white solid.

Purity

>90%

Shipping

Room temperature

Storage

Powder Form: Stable for 3 years when stored at -20°C.
In Solvent: Stable for 6 months when aliquoted and stored at -80°C

Research Use Only

For Research Use Only

Target Details

Target

PDGFRβ

Full Name

Platelet-Derived Growth Factor Receptor Beta

Alternative Names

Platelet-Derived Growth Factor Receptor Beta; CD140b

Gene ID

5159

Uniprot ID

P09619

Target Overview

Platelet-Derived Growth Factor Receptor Beta (PDGFRβ) is a cell surface receptor tyrosine kinase that plays a key role in normal cell development and angiogenesis. Upon binding its ligands, primarily Platelet-Derived Growth Factor-B (PDGF-B), the receptor dimerizes and becomes active through auto-phosphorylation. This initiates multiple intracellular signaling cascades that drive cell proliferation, survival, and migration. Aberrant activation or overexpression of PDGFRβ signaling is a well-established factor in the progression of various cancers, including glioblastoma, and in fibrotic diseases.

Publications